Okie S: ADHD in adults. N Engl J Med. 2006, 354: 2637-2641. 10.1056/NEJMp068113.
Article
CAS
PubMed
Google Scholar
Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS: Trends in medication treatment for ADHD. J Atten Disord. 2007, 10: 335-342. 10.1177/1087054707299597.
Article
PubMed
Google Scholar
Robison LM, Sclar DA, Skaer TL: Datapoints: trends in ADHD and stimulant use among adults: 1995–2002. Psychiatr Serv. 2005, 56: 1497-10.1176/appi.ps.56.12.1497.
Article
PubMed
Google Scholar
Nissen SE: ADHD Drugs and Cardiovascular Risk. N Engl J Med. 2006, 354: 1445-1448. 10.1056/NEJMp068049.
Article
CAS
PubMed
Google Scholar
Olfson M, Marcus SC, Zhang HF, Wan GJ: Stimulant dosing in the community treatment of adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008, 28: 255-257. 10.1097/JCP.0b013e31816740be.
Article
PubMed
Google Scholar
Brown GL, Hunt RD, Ebert MH, Bunney WE, Kopin IJ: Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. Psychopharmacology (Berl). 1979, 62: 133-140. 10.1007/BF00427126.
Article
CAS
Google Scholar
Berman SM, Kuczenski R, McCracken JT, London ED: Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry. 2009, 14 (2): 123-142. 10.1038/mp.2008.90.
Article
CAS
PubMed
Google Scholar
Thorpy M: Therapeutic advances in narcolepsy. Sleep Med. 2007, 8: 427-440. 10.1016/j.sleep.2007.03.004.
Article
PubMed
Google Scholar
Hardy SE: Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother. 2009, 7: 34-59. 10.1016/j.amjopharm.2009.02.006.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jordan LC, Hillis AE: Disorders of speech and language: aphasia, apraxia and dysarthria. Curr Opin Neurol. 2006, 19: 580-585. 10.1097/WCO.0b013e3280109260.
Article
PubMed
Google Scholar
Forsyth RJ, Jayamoni B, Paine TC: Monoaminergic agonists for acute traumatic brain injury. Cochrane Database Syst Rev. 2006, CD003984-4
Volkow ND, Wang GJ, Fowler JS, Molina PE, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas NR, et al: Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology. 2003, 166: 264-270.
CAS
PubMed
Google Scholar
Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, et al: Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005, 66: 253-259. 10.4088/JCP.v66n0215.
Article
PubMed
Google Scholar
Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T: A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006, 59: 829-835. 10.1016/j.biopsych.2005.09.011.
Article
CAS
PubMed
Google Scholar
Samuels JA, Franco K, Wan F, Sorof JM: Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006, 21: 92-95. 10.1007/s00467-005-2051-1.
Article
PubMed
Google Scholar
Findling RL, Short EJ, Manos MJ: Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry. 2001, 40: 525-529. 10.1097/00004583-200105000-00011.
Article
CAS
PubMed
Google Scholar
Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG: 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother. 2002, 36: 1142-1149.
Article
CAS
PubMed
Google Scholar
Wang AM, Suojanen JN, Colucci VM, Rumbaugh CL, Hollenberg NK: Cocaine- and methamphetamine-induced acute cerebral vasospasm: an angiographic study in rabbits. AJNR Am J Neuroradiol. 1990, 11: 1141-1146.
CAS
PubMed
Google Scholar
Rumbaugh CL, Bergeron RT, Scanlan RL, Teal JS, Segall HD, Fang HC, McCormick R: Cerebral vascular changes secondary to amphetamine abuse in the experimental animal. Radiology. 1971, 101: 345-351.
Article
CAS
PubMed
Google Scholar
De Silva DA, Wong MC, Lee MP, Chen CL-H, Chang HM: Amphetamine-Associated Ischemic Stroke: Clinical Presentation and Proposed Pathogenesis. J Stroke Cerebrovasc Dis. 2007, 16: 185-186. 10.1016/j.jstrokecerebrovasdis.2007.04.001.
Article
PubMed
Google Scholar
Chen JP: Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J Invasive Cardiol. 2007, 19: E89-E92.
Article
PubMed
Google Scholar
Conci F, D’Angelo V, Tampieri D, Vecchi G: Intracerebral hemorrhage and angiographic beading following amphetamine abuse. Ital J Neurol Sci. 1988, 9: 77-81. 10.1007/BF02334412.
Article
CAS
PubMed
Google Scholar
Watts DJ, McCollester L: Methamphetamine-induced myocardial infarction with elevated troponin I. Am J Emerg Med. 2006, 24: 132-134. 10.1016/j.ajem.2005.08.005.
Article
PubMed
Google Scholar
Thompson J, Thompson JR: Acute Myocardial Infarction Related to Methylphenidate for Adult Attention Deficit Disorder. J Emerg Med. 2007, 38 (1): 18-21.
Article
PubMed
Google Scholar
Bromberg-Marin G, Mahmud E, Tsimikas S: Spontaneous multivessel coronary vasospasm leading to cardiogenic shock. J Invasive Cardiol. 2007, 19: E85-E88.
PubMed
Google Scholar
Gandhi PJ, Ezeala GU, Luyen TT, Tu TC, Tran MT: Myocardial infarction in an adolescent taking Adderall. Am J Health Syst Pharm. 2005, 62: 1494-1497. 10.2146/ajhp040220.
Article
PubMed
Google Scholar
Kaye S, McKetin R, Duflou J, Darke S: Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007, 102: 1204-1211. 10.1111/j.1360-0443.2007.01874.x.
Article
PubMed
Google Scholar
Rumbaugh CL, Fang HC, Higgins RE, Bergeron RT, Segall HD, Teal JS: Cerebral microvascular injury in experimental drug abuse. Invest Radiol. 1976, 11: 282-294. 10.1097/00004424-197607000-00005.
Article
CAS
PubMed
Google Scholar
Rumbaugh CL, Bergeron RT, Fang HC, McCormick R: Cerebral angiographic changes in the drug abuse patient. Radiology. 1971, 101: 335-344.
Article
CAS
PubMed
Google Scholar
Brust JC: Vasculitis owing to substance abuse. Neurol Clin. 1997, 15: 945-957. 10.1016/S0733-8619(05)70357-1.
Article
CAS
PubMed
Google Scholar
Wooten MR, Khangure MS, Murphy MJ: Intracerebral hemorrhage and vasculitis related to ephedrine abuse. Ann Neurol. 1983, 13: 337-340. 10.1002/ana.410130321.
Article
CAS
PubMed
Google Scholar
Bostwick DG: Amphetamine induced cerebral vasculitis. Hum Pathol. 1981, 12: 1031-1033. 10.1016/S0046-8177(81)80262-6.
Article
CAS
PubMed
Google Scholar
Citron BP, Halpern M, McCarron M, Lundberg GD, McCormick R, Pincus IJ, Tatter D, Haverback BJ: Necrotizing angiitis associated with drug abuse. N Engl J Med. 1970, 283: 1003-1011. 10.1056/NEJM197011052831901.
Article
CAS
PubMed
Google Scholar
Ohta K, Mori M, Yoritaka A, Okamoto K, Kishida S: Delayed ischemic stroke associated with methamphetamine use. J Emerg Med. 2005, 28: 165-167. 10.1016/j.jemermed.2004.06.015.
Article
PubMed
Google Scholar
Schteinschnaider A, Plaghos LL, Garbugino S, Riveros D, Lazarowski A, Intruvini S, Massaro M: Cerebral arteritis following methylphenidate use. J Child Neurol. 2000, 15: 265-267. 10.1177/088307380001500414.
Article
CAS
PubMed
Google Scholar
Dickerson TJ, Yamamoto N, Ruiz DI, Janda KD: Immunological Consequences of Methamphetamine Protein Glycation. J Am Chem Soc. 2004, 126: 11446-11447. 10.1021/ja047690h.
Article
CAS
PubMed
Google Scholar
Treweek J, Wee S, Koob GF, Dickerson TJ, Janda KD: Self-vaccination by methamphetamine glycation products chemically links chronic drug abuse and cardiovascular disease. Proc Natl Acad Sci. 2007, 104: 11580-11584. 10.1073/pnas.0701328104.
Article
CAS
PubMed
PubMed Central
Google Scholar
Treweek JB, Dickerson TJ, Janda KD: Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology. Acc Chem Res. 2009, 42: 659-669. 10.1021/ar800247d.
Article
CAS
PubMed
PubMed Central
Google Scholar
Haning W, Goebert D: Electrocardiographic abnormalities in methamphetamine abusers. Addiction. 2007, 102 (Suppl 1): 70-75.
Article
PubMed
Google Scholar
Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK: A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007, 68: 93-101. 10.4088/JCP.v68n0113.
Article
CAS
PubMed
Google Scholar
Yap YG, Camm AJ: Drug induced QT prolongation and torsades de pointes. Heart. 2003, 89: 1363-1372. 10.1136/heart.89.11.1363.
Article
CAS
PubMed
PubMed Central
Google Scholar
Winegarden CR: From “prehypertension” to hypertension? Additional evidence. Ann Epidemiol. 2005, 15: 720-725. 10.1016/j.annepidem.2005.02.010.
Article
CAS
PubMed
Google Scholar
Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y: Is prehypertension a risk factor for cardiovascular diseases?. Stroke. 2005, 36: 1859-1863. 10.1161/01.STR.0000177495.45580.f1.
Article
PubMed
Google Scholar
Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, Levy D: Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease. N Engl J Med. 2001, 345: 1291-1297. 10.1056/NEJMoa003417.
Article
CAS
PubMed
Google Scholar
Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, O’Leary DH, Bryan RN, Anderson M, Lumley T: Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med. 2001, 161: 1183-1192. 10.1001/archinte.161.9.1183.
Article
CAS
PubMed
Google Scholar
Trugman JM: Cerebral arteritis and oral methylphenidate. Lancet. 1988, 1: 584-585.
Article
CAS
PubMed
Google Scholar
Sadeghian H: Lacunar stroke associated with methylphenidate abuse. Can J Neurol Sci. 2004, 31: 109-111.
Article
PubMed
Google Scholar
George AK, Kunwar AR, Awasthi A: Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin. J Child Adolesc Psychopharmacol. 2005, 15: 693-695. 10.1089/cap.2005.15.693.
Article
PubMed
Google Scholar
Information for Healthcare Professionals: Adderall and Adderall XR (amphetamine). U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084006.htm. 2005. Accessed 25 May 2012
Smith M: Cardiovascular Safety Warning Added for Stimulants for ADHD. MedPage Today. http://www.medpagetoday.com/Psychiatry/ADHD-ADD/3987. 2006. Accessed 25 May 2012
Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL: Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008, 117: 2407-2423. 10.1161/CIRCULATIONAHA.107.189473.
Article
PubMed
Google Scholar
Perrin JM, Friedman RA, Knilans TK, the Black Box Working Group the Section on Cardiology and Cardiac Surgery: Cardiovascular Monitoring and Stimulant Drugs for Attention-Deficit/Hyperactivity Disorder. Pediatrics. 2008, 122: 451-453. 10.1542/peds.2008-1573.
Article
PubMed
Google Scholar
American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr. 2008, 29: 335-10.1097/DBP.0b013e31318185dc14.
Updating of Product Monograph of Attention Deficit Hyperactivity Disorder (ADHD) Drugs - For Health Professionals. Health Canada. http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2006/adhd-tdah_medic_hpc-cps-eng.php. 2006. Accessed 25 May 2012
Conway J, Wong KK, O’Connell C, Warren AE: Cardiovascular Risk Screening Before Starting Stimulant Medications and Prescribing Practices of Canadian Physicians: Impact of the Health Canada Advisory. Pediatrics. 2008, 122: e828-e834. 10.1542/peds.2008-0276.
Article
PubMed
Google Scholar
Thomas PE, Carlo WF, Decker JA, Cannon BC, Kertesz NJ, Friedman RA, Kim JJ: Impact of the American Heart Association Scientific Statement on Screening Electrocardiograms and Stimulant Medications. Arch Pediatr Adolesc Med. 2011, 165: 166-170. 10.1001/archpediatrics.2010.278.
Article
PubMed
Google Scholar
Australian Guidelines on Attention Deficit Hyperactivity Disorder (ADHD). Royal Australasian College of Physicians. http://www.nhmrc.gov.au/guidelines/publications/ch54. 2008. Accessed 25 May 2012
FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm. 2010. Accessed 25 May 2012
Pollack A: F.D.A. Rejects Qnexa, a Third Weight-Loss Drug. The New York Times. http://www.nytimes.com/2010/10/29/health/policy/29drug.html?_r=1&partner=rss&emc=rss. 2010. Accessed 25 May 2012
Pollack A: Advisory Panel Favors Approval for Weight-Loss Drug. The New York Times. http://www.nytimes.com/2012/02/23/business/fda-advisory-panel-backs-diet-drug.html?_r=1. 2012. Accessed 25 May 2012
Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A: Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2007, 120: e1494-e1501. 10.1542/peds.2007-0675.
Article
PubMed
Google Scholar
Winterstein AG, Gerhard T, Shuster J, Saidi A: Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009, 124: e75-e80. 10.1542/peds.2008-3138.
Article
PubMed
Google Scholar
McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC: Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009, 32: 1089-1096. 10.2165/11317630-000000000-00000.
Article
PubMed
Google Scholar
Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T: Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009, 166: 992-1001. 10.1176/appi.ajp.2009.09040472.
Article
PubMed
Google Scholar
Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, Daniel GW, Cziraky MJ, Hennessy S: Cardiovascular Events and Death in Children Exposed and Unexposed to ADHD Agents. Pediatrics. 2011, 127: 1102-1110. 10.1542/peds.2010-3371.
Article
PubMed
PubMed Central
Google Scholar
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, et al: ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults. N Engl J Med. 2011, 365: 1896-1904. 10.1056/NEJMoa1110212.
Article
CAS
PubMed
Google Scholar
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA: Attention Deficit Hyperactivity Disorder Medications and Risk of Serious Cardiovascular Disease in Children and Youth. Effective Health Care Program Research Report No. 12-EHC006-EF. (Prepared by Vanderbilt and HMORN DEcIDE Centers under Contract Nos. HHSA HHSA290-2005-0042-I and HHSA290-2005-0033-I, respectively.). Agency for Healthcare Research and Quality. http://www.effectivehealthcare.ahrq.gov/ehc/products/395/885/DEcIDE35_YouthADHD_20111031.pdf. 2011. Accessed 25 May 2012
Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, Marcus SC: Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012, 51: 147-156. 10.1016/j.jaac.2011.11.008.
Article
PubMed
Google Scholar
Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003, 26: 729-740. 10.2165/00002018-200326100-00006.
Article
CAS
PubMed
Google Scholar
Holick CN, Turnbull BR, Jones ME, Chaudhry S, Bangs ME, Seeger JD: Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol. 2009, 29: 453-460. 10.1097/JCP.0b013e3181b2b828.
Article
CAS
PubMed
Google Scholar
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, et al: ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011, 306: 2673-2683. 10.1001/jama.2011.1830.
Article
CAS
PubMed
PubMed Central
Google Scholar
Habel LA, Cooper WO, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Quinn VP, Fireman BH, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV: ADHD Medications and Risk of Serious Coronary Heart Disease in Young and Middle-Aged Adults. Effective Health Care Program Research Report No. 36. (Prepared by Vanderbilt DEcIDE Center and HMO Research Network DEcIDE Center under Contract Nos. HHSA 290-2005-0042-I and HHSA 290-2005-0033-I). AHRQ Publication No. 12-EHC011-EF. Agency for Healthcare Research and Quality. http://www.effectivehealthcare.ahrq.gov/ehc/products/394/884/DEcIDE36_ADHDMeds-Adults_20111220.pdf. 2011. Accessed 25 May 2012
Schelleman H, Bilker WB, Kimmel SE, Daniel GW, Newcomb C, Guevara JP, Cziraky MJ, Strom BL, Hennessy S: Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry. 2012, 169: 178-185. 10.1176/appi.ajp.2011.11010125.
Article
PubMed
Google Scholar
Arias E, Anderson R, Hsiang-Ching K, Murphy S, Kochanek K: National vital statistics reports. Deaths: Final data for 2001. 2003, National Center for Health Statistics, Hyattsville, Maryland, 3-
Google Scholar